Paris, London and Milan-based Sofinnova Partners has recently announced the closing of their oversubscribed late-stage healthcare crossover fund at €445 Million. This now comprises the largest crossover investor dedicated late-stage biopharma and medtech fund in Europe. Sofinnova is expected to Maintain their focus on European companies in need of scale-up capital, but will also support […] The post Sofinnova Partners closes crossover fund at €445 Million appeared first on Tech.eu.